Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTION-DDR: Carboplatin + Docetaxel in mCRPC with DDR Alterations
NCT06439225Phase 3Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Dec 2024
- Primary completion
- Sep 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised trial of carboplatin in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Overall Survival at 5.25 years. Started Dec 2024; status: recruiting.
02
Drugs
carboplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06439225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439225.